A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2014; you can also visit the original URL.
The file type is
The Center of Molecular Immunology (CIM) is a center in Cuba devoted to the research, development and manufacturing of biotechnological products. CIMAvax ® EGF is a vaccine for the treatment of non-small cell lung cancer patients (NSCL). Purpose: The aim of this work is to evaluate the effects of some potential prognostic factors on the overall survival of patients treated with CIMAvax ® EGF vaccine, based on data collected in a phase II and a phase III clinical trials. Methods: The stratifieddoi:10.4236/jct.2013.48a002 fatcat:3am2pq4yiraxla4d5o55g4mawe